Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors
- 10 April 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (8) , 3281-3295
Abstract
Discoidin domain receptor 1 (DDR1) is an emerging potential molecular target for new anticancer drug discovery. We have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors. The two most promising compounds (7rh and 7rj) inhibited the enzymatic activity of DDR1, with IC50 values of 6.8 and 7.0 nM, respectively, but were significantly less potent in suppressing the kinase activities of DDR2, Bcr-Abl, and c-Kit. Further study revealed that 7rh bound with DDR1 with a Kd value of 0.6 nM, while it was significantly less potent to the other 455 kinases tested. The S(35) and S(10) selectivity scores of 7rh were 0.035 and 0.008, respectively. The compounds also potently inhibited the proliferation of cancer cells expressing high levels of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity. Preliminary pharmacokinetic studies suggested that they possessed good PK profiles, with oral bioavailabilities of 67.4% and 56.2%, respectively.Keywords
This publication has 68 references indexed in Scilit:
- Discoidin domain receptor tyrosine kinases: new players in cancer progressionCancer and Metastasis Reviews, 2012
- DDR1 Receptor Tyrosine Kinase Promotes Prosurvival Pathway through Notch1 ActivationJournal of Biological Chemistry, 2011
- Collective cell migration requires suppression of actomyosin at cell–cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6Nature Cell Biology, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cellsBritish Journal of Cancer, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinomaBritish Journal of Cancer, 2007